September 17, 2021
Takeda Pharmaceutical said on September 15 that the US FDA has granted approval for Exkivity (mobocertinib) for the treatment of certain adult patients with EGFR exon 20 insertion mutation-positive metastatic non-small cell lung cancer (NSCLC). The drug was approved for...read more